http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020507077-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020507077-A |
| titleOfInvention | PROADM as a marker for adverse events |
| abstract | The present invention relates to the diagnosis, prognosis, risk assessment, and / or risk stratification of an adverse event in a subject, particularly death. The invention relates to a method comprising determining the level of proadrenomedullin (proADM) in a sample of said subject, wherein said level of proADM is an indicator of said adverse event of said subject, Is compared to a reference level of proADM, and the adverse event of the subject is identified based on the comparison. The invention further relates to a kit for performing the method of the invention. |
| priorityDate | 2017-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 644.